University of Minnesota professor and endocrinologist Elizabeth Seaquist, M.D., named President of Medicine and Science of the American Diabetes Association
You are here
[News release adapted from American Diabetes Association]
University of Minnesota professor of medicine and endocrinologist Elizabeth Seaquist, M.D., was recently named President of Medicine and Science, on the Board of Directors for the American Diabetes Association, the nation’s largest voluntary health organization leading the fight to Stop Diabetes®.
As President of Medicine and Science, Seaquist will serve as the co-principal spokesperson with the President, Health Care and Education of the Association on science, health care and educational matters, and will assist with oversight of the Association’s business affairs. Additionally, she will work closely with the Association’s volunteers and staff on activities and initiatives in support of the organization’s mission during her tenure.
“As a researcher and clinician, my professional goal has been to improve the lives of people with diabetes,” said Seaquist. “As the President of Medicine and Science, I will be able to advance this goal on a national and international basis. I look forward to serving people with diabetes as an Association leader.”
Seaquist has been a member of the American Diabetes Association since 1987 and has served at the national level on the Research Policy Committee, the Research Grant Review Committee and the Scientific Sessions Meeting Planning Committee. She currently serves on the editorial board for Diabetes Care. At the local level, she served a two-year term as co-chair of the American Diabetes Association EXPO in her home city of Minneapolis and leads a successful Tour de Cure team.
Seaquist is a clinical investigator interested in the complications of diabetes. She was awarded a Distinguished Clinical Scientist Award by the American Diabetes Association in 2009. Her research focuses on the effect of diabetes on brain metabolism, structure and function. She also directs the University of Minnesota site for two NIH-funded clinical trials, including the GRADE study that is currently enrolling patients with newly diagnosed type 2 diabetes into a study that will determine the best drug to add to a metformin-based regimen (http://grade.bsc.gwu.edu or email@example.com).
Seaquist is also the principal investigator on the NIH training grant for fellows in endocrinology and diabetes at the University of Minnesota, and maintains an active clinical practice. Seaquist also holds the Pennock Family Chair in Diabetes Research at the University.
“Dr. Seaquist has served the Association for many years and has always been an asset,” said Larry Hausner, M.B.A., chief executive officer of the American Diabetes Association. “We are looking forward to her more prominent role on the board and the expertise she will bring to help us move our mission forward.”
Diabetes is a serious disease that affects the body’s ability to produce or respond properly to insulin, a hormone that allows blood glucose to enter the cells of the body and be used for energy. Recent estimates project that as many as one in three American adults will have diabetes by 2050, unless we take steps to Stop Diabetes.